Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-07-09

Clinical Trial Update: The Feasibility of Florbetapir Quantitation in Europe [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the feasibility of quantifying florbetapir in Europe for Alzheimer's disease; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Florbetapir (Florbetapir)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED | Results posted: 2015-07-09